Gilead’s Veklury wins expanded FDA nod for moderate COVID-19 patients despite mixed data esagonowsky Mon, 08/31/2020 – 11:27

Understanding bottleneck effects in the translation of bacterial proteins can lead to a more effective combination of antibiotics.

ESC: Merck’s Steglatro shows limited promise with heart failure hospitalization data kblankenship Sun, 08/30/2020 – 15:44

ESC: AstraZeneca’s Farxiga cuts kidney disease risks by 39% in trial that could ‘rewrite’ the treatment textbook kblankenship […]

ESC: Novartis’ Entresto racks up a heart failure study win—but it’s a mixed one kblankenship Sat, 08/29/2020 – […]

ESC: Pfizer, BMS’ Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study kblankenship […]

ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha kblankenship Fri, 08/28/2020 – 18:15

ESC: Eli Lilly, Boehringer’s Jardiance cuts CV events by 25% in Farxiga-matching heart failure trial kblankenship Fri, 08/28/2020 […]

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT

Updated Date: Fri, 21 Aug 2020 00:00:00 EDT